Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates

Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens

(2014) Riina-Minna Väänänen et al.   UROLOGY

Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens

(2013) Riina-Minna Väänänen et al.   CLINICAL BIOCHEMISTRY

Preservation of nucleic acids and tissue morphology in paraffin-embedded clinical samples: comparison of five molecular fixatives

(2013) Synnöve Staff et al.   JOURNAL OF CLINICAL PATHOLOGY

Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis

(2012) Grégoire Robert et al.   PROSTATE

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice

(2011) Geert JLH van Leenders et al.   MODERN PATHOLOGY

ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice

(2009) Scott A. Tomlins et al.   EUROPEAN UROLOGY

Evidence for field cancerization of the prostate

(2009) Larisa Nonn et al.   PROSTATE

Cytopathology

(2008)   MODERN PATHOLOGY

Quantitative real-time RT-PCR assay for PCA3

(2007) Riina-Minna Väänänen et al.   CLINICAL BIOCHEMISTRY